Evaluation of sex differences in the pharmacokinetics of ranitidine in humans

Journal of Clinical Pharmacology

Volumn 36, Issue 8, 1996, Pages 748-751

  Abad Santos, Francisco ^a   Carcas, Antonio J ^a   Guerra, Pedro ^a   Govantes, Carlos ^a   Montuenga, Carlos ^b   Gómez, Estrella ^b   Fernández, Antonio ^b   Frias, Jesus ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Normon SA Laboratories   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

RANITIDINE;

ADULT; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

EID: 0029794303     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04245.x     Document Type: Article

References (15)

1. Walle T, Walle K, Cowart TD, Conradi EC: Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther 1989; 46:257-263.
2. Hooper WD, Qing MS: The influence of age and gender on the stereoselective metabolism and pharmacokinetics of mephobarbital in humans. Clin Pharmacol Ther 1990; 48:633-640.
3. Bonate PL: Gender-related differences in xenobiotic metabolism. J Clin Pharmacol 1991; 31:684-690.
4. Harris RZ, Benet LZ, Schwartz JB: Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50:222-239.
5. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS: Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 1982; 24:267-303.
6. Roberts CJC: Clinical pharmacokinetics of ranitidine. Clin Pharmacokinet 1984; 9:211-221.
7. Grant SM, Langtry HD, Brogden RN: Ranitidine: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 1989; 37:801-870.
8. Morichau-Bauchant M, Houin G, Mavier P, Alexandre C, Dhumeaux D: Pharmacokinetics and bioavailability of ranitidine in normal subjects and cirrhotic patients. Dig Dis Sci 1986; 31:113-118.
9. Saket M, Arafat T, Awad R, Ibrahim H, Saleh M, Sallam E, et al: A bioequivalence study of two brands of ranitidine tablets. Curr Ther Res 1989; 46:924-931.
10. Salem MS, Gharaibeh AM, Alkaysi HN, Badwan A: High-performance liquid chromatographic analysis of ranitidine in plasma and urine. J Clin Pharm Ther 1988; 13:351-357.
11. Hauschke D, Steinijans VW, Diletti E: A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicicol 1990; 28:72-78.
12. World Health Organization: Interchangeable multi-source pharmaceutical products: WHO draft guideline on marketing authorization requeriments. WHO Drug Information 1994; 8:71-84.
13. Garg DC, Eshelman FN, Weidler DJ: Pharmacokinetics of ranitidine following oral administration with ascending doses and with multiple-fixed doses. J Clin Pharmacol 1985; 25:437-443.
14. Shim CK, Hong JS: Inter- and intrasubject variations of ranitidine pharmacokinetics after oral administration to normal male subjects. J Pharm Sci 1989; 78:990-994.
15. Hunt CM, Westerkam WR, Stave GM: Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992; 44:275-283.